{"id":"hgp0904","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vaginal dryness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HGP0904 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than modulation. The drug is designed to overcome resistance mechanisms that develop with standard endocrine therapies in estrogen receptor-positive breast cancer.","oneSentence":"HGP0904 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:12.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT04074551","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-07-16","conditions":"Hypertension, Dyslipidemias","enrollment":145},{"nctId":"NCT04322266","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-12-21","conditions":"Healthy","enrollment":61},{"nctId":"NCT04081844","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-05-03","conditions":"Healthy","enrollment":31},{"nctId":"NCT02587988","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of HCP1302","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-09","conditions":"Erectile Dysfunction, Hypertension","enrollment":232},{"nctId":"NCT02243319","phase":"PHASE1","title":"Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT02899455","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-07","conditions":"Hypertension, Hyperlipidemia","enrollment":146},{"nctId":"NCT02387554","phase":"PHASE1","title":"Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-08","conditions":"Hypertension(HTN)","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["amlodipine"],"phase":"phase_3","status":"active","brandName":"HGP0904","genericName":"HGP0904","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HGP0904 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}